Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A phase II, single-arm, open-label study evaluating feasibility, safety and efficacy of
combined chemotherapy and pembrolizumab as neoadjuvant/adjuvant therapy in stage IIa-IIIB
NSCLC adult patients followed by adjuvant PD-(L)1 inhibitor treatment for up to 1 year